WO2001030988A1 - Procedes de fabrication et d'utilisation de reactifs de voies de synthese d'acides gras - Google Patents

Procedes de fabrication et d'utilisation de reactifs de voies de synthese d'acides gras Download PDF

Info

Publication number
WO2001030988A1
WO2001030988A1 PCT/US2000/029451 US0029451W WO0130988A1 WO 2001030988 A1 WO2001030988 A1 WO 2001030988A1 US 0029451 W US0029451 W US 0029451W WO 0130988 A1 WO0130988 A1 WO 0130988A1
Authority
WO
WIPO (PCT)
Prior art keywords
acp
ketoacyl
polypeptide
high throughput
nadph
Prior art date
Application number
PCT/US2000/029451
Other languages
English (en)
Other versions
WO2001030988A8 (fr
Inventor
Walter Dewolf, Jr.
Howard Kallender
John T. Lonsdale
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham Plc filed Critical Smithkline Beecham Corporation
Priority to US10/089,019 priority Critical patent/US6951729B1/en
Publication of WO2001030988A1 publication Critical patent/WO2001030988A1/fr
Publication of WO2001030988A8 publication Critical patent/WO2001030988A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes

Definitions

  • the present invention relates to fatty acid synthesis pathway reagents, including isolated pathway enzymes and substrates. Also provide are methods using such reagents to identify bioactive agents affecting fatty acid synthesis. Background of the Invention
  • the pathway for the biosynthesis of saturated fatty acids is very similar in prokaryotes and eukaryotes.
  • Vertebrates possess a type I fatty acid synthase (herein “FAS”) in which all of the enzymatic activities are encoded on one multifunctional polypeptide, the mature protein being a homodimer.
  • FAS type I fatty acid synthase
  • ACP acyl carrier protein
  • ACP is an integral part of the complex.
  • ACP acyl carrier protein
  • Mycobacteria are unique in that they possess both type I and II FASs.
  • malonyl-ACP is synthesized from ACP and malonyl-CoA by FabD, malonyl CoA:ACP transacylase. Then, malonyl-ACP is condensed with acetyl- CoA by FabH, acetoacetyl-ACP synthase III. The next step in the elongation cycle is ketoester reduction by ⁇ -ketoacyl-ACP reductase (herein "FabG").
  • coli and Haemophilus influenzae have FabB and FabF enzymes, while at least certain gram positive bacteria, such as staphylococci and streptococci, have only one corresponding enzyme which is most homologous to FabF but functions as FabB.
  • the sequence of the E. coli apo-ACP has been described by Rawlings and Cronan (Rawlings, M.
  • Cerulenin and thiolactomycin are potent inhibitors of bacterial fatty acid biosynthesis. Extensive work with these inhibitors has proved that this biosynthetic pathway is essential for bacterial viability. No marketed antibiotics are targeted against fatty acid biosynthesis, therefore it is unlikely that novel antibiotics would be rendered inactive by known antibiotic resistance mechanisms. There is an unmet need for developing new classes of antibiotic compounds, such as those that target bacterial FAS.
  • the present invention provides a method for the attachment of a phosphopantetheinyl prosthetic group to apo-ACP, preferably at a serine, especially at Ser 37 of E. coli apo-ACP. Further method are also provided for making Apo-ACP, holo-ACP, and acetyl-
  • the invention still further provided a method for the conversion of malonyl-CoA to malonyl-ACP via FabD transacylase.
  • Another method of the invention provides the synthesis of D-3-Hydroxybutyryl- ACP from malonyl-ACP, the synthesis of crotonoyl-ACP, the syntheseis of butyryl-ACP
  • the invention also provides a high throughput screening method for biological agents affecting fatty acid biosynthesis, the method comprising: (A) providing a reaction mixture comprising: (1) (a) an acyl carrier moiety or (b) enzymes and precursers sufficient to generate the acyl carrier moiety; (2) a bacterial enzymatic pathway comprising at least two (preferably three, four or five) consecutively acting enzymes selected from the group consisting of: (a) malonyl-CoA:ACP transacylase, (b) ⁇ -ketoacyl-ACP synthase III, (c) NADPH-dependent ⁇ -ketoacyl-ACP reductase, (d) ⁇ -hydroxyacyl-ACP dehydrase, and (e) enoyl-ACP reductase; and (3) substrates and cofactors required for the operation of the enzymes; (B) contacting the reaction mixture with a prospective bioactive agent; (C) conducting a high throughput measurement of the activity of the enzymatic
  • the invention further provides a screening method for biological agents affecting fatty acid biosynthesis: (A) providing a reaction mixture comprising: (1) (a) an acyl carrier moiety or (b) enzymes and precursers sufficient to generate the acyl carrier moiety;
  • a bacterial enzymatic pathway comprising at least two consecutively acting enzymes selected from: (a) malonyl-CoA:ACP transacylase, (b) ⁇ -ketoacyl-ACP synthase III, (c)
  • NADPH-dependent ⁇ -ketoacyl-ACP reductase NADPH-dependent ⁇ -ketoacyl-ACP reductase, (d) ⁇ -hydroxy acyl -ACP dehydrase, and (e) enoyl-ACP reductase; and (3) substrates and cofactors required for the operation of the enzymes; (B) contacting the reaction mixture with a prospective bioactive agent; (C) measuring the activity of the enzymatic pathway; and (D) determining if the contacting altered the activity of the enzymatic pathway, wherein at least one of the following applies:
  • the enoyl-ACP reductase is a NADH-specific enoyl-ACP reductase; or (2) the ⁇ -ketoacyl-ACP synthase III is a ⁇ -ketoacyl-ACP synthase III derived from E. coli. or H. influenzae; or (3) NADPH is provided to the reacting step in a constant amount such that the NADH consumption by enoyl-ACP reductase (Fabl) can be quantitated accurately and without interference, or an amount effective to reduce NADH consumption by more
  • Fabl enoyl-ACP reductase
  • NADPH-dependent enzymes such as NADPH-dependent ⁇ -ketoacyl-ACP reductase
  • NADPH-dependent ⁇ -ketoacyl-ACP reductase is derived from Streptococcus, Staphylococcus or Pseudomonas.
  • FIG 1 illustrates the enzyme cycle of FAS, type II.
  • Figure 2 illustrates a configuration for a continuous assay.
  • FIG. 3 illustrates data from an SPA-based screening assay.
  • the invention provides methods for making acyl-ACP's.
  • Apo-ACP is needed for the production of certain acyl-ACP's.
  • E. coli apo-ACP may be used.
  • the polynucleotide and polypeptide sequences of E. coli apo-ACP are shown below. Nucleotide sequence of E.
  • SEQ ID NO: 331 ATGAGCACTATCGAAGAACGCGTTAAGAAAATTATCGGCGAACAGCTGGGCGTTAAGCAGGAAGAAGT TACCAACAATGCTTCTTTCGTTGAAGACCTGGGCGCGGATTCTCTTGACACCGTTGAGCTGGTAATGG CTCTGGAGAAGAGTTTGATACTGAGATTCCGGACGAAGAAGCTGAGAAAATCACCACCGTTCAGGCTG CCATTGATTACATCAACGGCCACCAGGCG
  • a preferred method of the invention provides for the attachment of a phosphopantetheinyl prosthetic group to apo-ACP.
  • An example of such attachment is shown in the E. coli apo-ACP protein, which indicates the position for the attachment of the phosphopantetheinyl prosthetic group (underlined and in bold).
  • acyl-ACP's Structures of acyl-ACP's are known in the art (see, for, example, Prescott, D.J. and Vagelos, P.R. ( ⁇ 972) Adv. Enzymol. 36, 269-311). These acyl-ACP's are variants of holo- ACP comprising a phosphopantetheinyl group conjugated with acyl groups.
  • Holo-ACP is derived from apo-ACP.
  • Apo-ACP is a preferred starting material in the methods of the invention.
  • Ser 37 (underlined and in bold) is conjugated to the phosphopantetheinyl moiety of coenzyme A.
  • Table 1 The structure of holo-ACP is shown below in Table 1.
  • Apo-ACP may be produced as set forth herein, such as, for example, by overexpression in an E. coli expression system.
  • the protein may be isolated and partially purified, followed by further purification, such as using HPLC.
  • Holo-ACP may be synthesized as set forth herein, such as by isolation from bacteria. Once isolated, Holo-ACP synthesis may be confirmed by FPLC, and the functionality as a substrate tested using an FabD reaction, an example of which is set forth elsewhere herein.
  • Acetyl-ACP may be synthesized as set forth herein.
  • acetyl- ACP is synthesized via an ACP synthase reaction, an example of which is set forth elsewhere herein.
  • Acetyl-ACP may then be purified by FPLC, or another purification method. While acetyl-ACP is not known to be an intermediate of fatty acid biosynthesis, the invention provides that it is an inhibitor of FabH.
  • a reaction converting malonyl-CoA to malonyl-ACP via FabD transacylase activity is provided, whereby ACP's are separated from reducing agent, and then malonyl-ACP is concentrated using known methods.
  • Reaction mixtures contained buffer, malonyl-CoA, apo-ACP, and ACP synthase.
  • progress of the reaction may be monitored, such as by FPLC, assess conversion of apo-ACP to malonyl-ACP.
  • Apo-ACP , ACP synthase and buffer are combined and incubated.
  • CoA is added and incubated. Formation of acetoacetyl-ACP may be monitored, such as by mass spectral analysis, or another known method, to assess reaction completion.
  • the reaction mixture may be purified by chromatography.
  • D-3-Hydroxybutyryl-ACP was synthesized from malonyl-ACP in a coupled enzyme system comprising buffer, malonyl-ACP, acetyl-CoA, NADPH, FabH enzyme and FabG enzyme.
  • the reaction was initiated by addition of FabH enzyme.
  • the product of the reaction is purified as described above for apo-ACP, or as described elsewhere herein.
  • the concentration of the D-3-hydroxybutyryl-ACP may be determined by amino acid analysis or by using a functional assay consisting of FabZ coupled through Fabl.
  • crotonoyl-ACP was carried out using apo-ACP in buffer, to which is added crotonoyl-CoA and ACP synthase. Reaction completion may be measured using any known method, such as by mass spectrometry. In a preferred embodiment, conversion is complete when no detectable by-products are observed. The reaction mixture may then be purified, such as by using a column. Isolated crotonoyl-ACP is obtained carried out as set forth elsewhere herein for apo-ACP.
  • Butyryl-ACP is synthesized in reaction mixtures comprising buffer butyryl-CoA, apo-ACP, and ACP synthase, preferably in total volumes up to 50 mL. Conversion of apo- ACP to butyryl-ACP is achieved in the above reaction, and reaction progression may be measured, such as by FPLC. For example, FPLC will show disappearance of apo-ACP substrate and emergence of a new product peak.
  • butyryl-ACP may be quantitated, such as by measuring its absorbance, preferably at 280 nm, or in a functional assay, such as utilizing malonyl-ACP and a FabF/FabG coupled, spectrophotometric assay measuring the disappearance of NADPH, preferably at 340 nm.
  • a FabD enzymatic assay may be carried out as follows. Labeled malonyl-ACP formation is specifically measured using labeled malonyl-CoA and holo-ACP. The substrate labeled malonyl-CoA and labeled malonyl-ACP may be differentiated via their chemical or physical characteristics, such as by solubility in TCA.
  • Reaction conditions typically are preferably comprise buffer, malonyl-CoA, labeled malonyl-CoA, and holo- ACP.
  • FabD enzyme is added last to start the reaction. The reaction is stopped, and the proportion of products and remaining reagents is assessed, such as by using a filter assay of TCA precipitates.
  • Another method provided by the invention is a coupled assay.
  • This assay relies, in part, on the observation that a product of a malonyl-CoA:ACP transacylase reaction is free coenzyme A. This fact is exploited by coupling a FabD reaction with an excess of ⁇ -ketoglutarate dehydrogenase.
  • Preferred reaction mixtures comprise NAD + , ⁇ -ketoglutaric acid, ⁇ -ketoglutarate dehydrogenase, malonyl-CoA, holo-ACP and FabD.
  • NAD + reduction may be followed, such as spectroscopically, preferably at 340 nm.
  • a preferred FabH assay of the invention follows the incorporation of labeled acetyl- CoA versus labeled acetoacetyl-ACP.
  • assay mixtures comprise either labeled acetyl-CoA and malonyl-ACP, or variable concentrations of substrate, in a preferred embodiment, reactions are initiated by the addition of FabH. Reactions are preferably terminated either by adding sample aliquots from reaction tubes comprising TCA and BSA, or by adding TCA and BSA directly into a reaction plate. Proteins in the stopped reactions are recovered by filtration, or using another known method, and the amount of the protein of interest is detected, or quantitated.
  • the invention further provides a FabH coupled assay.
  • the FabH/FabG coupled assay is preferably performed in a reaction mixture comprising malonyl-ACP, acetyl-CoA, NADPH and FabG.
  • the reaction mixture is then incubated at an appropriate temperature, and FabH is added to start the reaction.
  • a still further embodiment of the invention is a FabG screening assay. This assay is run using reaction mixtures comprising buffer, NADPH, acetoacetyl-ACP, and FabG enzyme. It is preferred that the NADPH is preincubated with the FabG prior to their addition to the assay vessel.
  • a FabZ/I coupled assay is also provided by the invention.
  • This assay uses FabZ and Fabl enzymes. It is preferred that the assay is performed using a reaction mixture comprising buffer, NADH, Fabl and FabZ. It is preferred that a substrate, 3-OH-butyryl- ACP, is diluted in buffer and incubated at the appropriate temperature. It is further preferred that the reaction is started by adding 3-OH-butyryl-ACP to the reaction mixture.
  • a Fabl screening assay is also provided wherein assay mixtures comprise NaADA, ADA ("ADA" is N-[2-acetamido]-2-iminodiacetic acid), crotonoyl-ACP, NADPH, and an appropriate dilution Fab I. It is preferred that inhibitors are provided at concentrations varied over the range of 0.01-10 ⁇ M. The consumption of NADPH may be monitored by following the change in absorbance, preferably at 340 nm.
  • a FabF screening assay is also provided using a FabG coupled system comprising NADPH, malonyl-ACP, butyryl-ACP, and FabG enzyme.
  • Compounds are added to the above mixture, and the reaction is started, preferably by the addition of FabF enzyme.
  • Incubations are carried out, during which time the consumption of NADPH may be monitored, preferably optically at 340 nm.
  • acyl-ACP's and the FAS pathway enzymes of the invention may be obtained from any organism provided herein; however, it is preferred that they are obtained from Escherichia coli and/or pathogenic bacteria.
  • the invention also relates to polypeptides and polynucleotides of the Fab (fatty acid biosynthesis) family, hereinafter referred to as "fab", as described in greater detail below, and methods of using such polynucleotides and polypeptides in screening for agonists and antagonists.
  • the invention relates to polypeptides and polynucleotides of a fab of an organism of the invention, preferably streptococci, staphylococci, Escherichia coli or Haemophilus influenzae, that is related by amino acid sequence homology to fab polypeptide.
  • the invention relates especially to fab having a nucleotide and amino acid sequences set out in Table 2 as SEQ ID NO: 1, 4, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29 or 31 and SEQ ID NO: 2, 3, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 or 32 respectively.
  • sequences recited in the Sequence Listing below as "DNA” represent an exemplification of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including ribopolynucleotides.
  • fab polypeptides and polynucleotides include ACP polypeptides and polynucleotides, particularly those more specifically described elsewhere herein.
  • the invention encompasses each nucleic acid or protein sequence described herein, as well as the vectors and host cells described.
  • Staphylococcus aureus WCUH29 His6-fabD polynucleotide sequence [SEQ ID NO: 1] (999 base pairs, including stop codon).
  • Staphylococcus aureus WCUH29 fabG polynucleotide sequence [SEQ ID NO:7] (741 base pairs including stop codon).
  • Staphylococcus aureus fabl polynucleotide sequence [SEQ ID NO: 11] (774 base pairs including stop codon). 5 ' -ATGGGCTTAAATCTTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTA
  • Staphylococcus aureus fabF polynucleotide sequence [SEQ ID NO: 13] (1245 base pairs, including stop codon).
  • Streptococcus Pneumoniae FabH polynucleotide sequence [SEQ ID NO: 15] (975 base pairs including stop codon). 5 ' -ATGGCTTTTGCAAAAATAAGTCAGGTTGCTCATTATGTGCCAGAGCAAGTGGTTACAAA TCACGACTTGGCTCAGATTATGGATACCAATGATGAGTGGATTTCAAGTCGAACGGGAATACGACAA AGGCATATTTCAAGAACAGAATCTACCAGTGATTTGGCTACAGAGGTTGCTAAGAAACTGATGGCAA AAAAGCTGGAATAACAGGAAAAGAACTGGATTTTATCATCCTAGCTACCATTACTCCAGATTCGATGAT GCCCTCTACAGCTGCTCGTGTTCAAGCTAATATTGGCGCTAATAAAGCCTTTGCTTTTGACTTAACC GCGGCTTGCAGTGGATTTGTATTTGCTCTTTCAACTGCTGAAAAGTTTATCGCTTCTGGTCGCTTTC AAAAAGGCTTGGTGATTGGTAGTGAAAAGTTTATCGCTT
  • Escherichia coli FabH ORF polynucleotide sequence [SEQ ID NO: 21]. See, Tsay et al., J. Biol. Chem. 267:6807-6814, 1992. (1 ,273 base pairs, including stop codon) 5 ' -TCGCGATTGAACAGGCAGTGCAGGCGGTGCAGCGACAAGTTCCTCAGCGAATTGCCGC
  • Staphylococcus aureus WCUH29 ACP polypeptide sequence deduced from a polynucleotide sequence in this table [SEQ ID NO: 26] (262 amino acids).
  • H influenzae (strain 689) FabH polynucleotide sequence [SEQ ID NO 31] (951 base pairs including stop codon)
  • H influenzae (strain 689) FabH polypeptide sequence deduced from a polynucleotide sequence in this table [SEQ ID NO 32] (316 amino acids)
  • a deposit comp ⁇ sing a Streptococcus pneumoniae 0100993 strain has been deposited with the National Collections of Industrial and Marine Bacte ⁇ a Ltd. (herein "NCDVIB"), 23 St. Machar Drive, Aberdeen AB2 IRY, Scotland on 11 Ap ⁇ l 1996 and assigned deposit number 40794. The deposit was described as Streptococcus pneumoniae 0100993 on deposit. On 17 April 1996 a Streptococcus pneumoniae 0100993 DNA library in E. coli was similarly deposited with the NCIMB and assigned deposit number 40800.
  • the Streptococcus pneumoniae strain deposit is referred to herein as "the deposited strain” or as "the DNA of the deposited strain.”
  • a deposit comprising a Staphylococcus aureus WCUH 29 strain has been deposited with the National Collections of Industrial and Marine Bacteria Ltd. (herein "NCIMB"), 23 St. Machar Drive, Aberdeen AB2 IRY, Scotland on 1 1 September 1995 and assigned NCIMB Deposit No. 40771, and referred to as Staphylococcus aureus WCUH29 on deposit.
  • the Staphylococcus aureus strain deposit is refe ⁇ ed to herein as "the deposited strain” or as "the DNA of the deposited strain.”
  • the deposited strains comprise full length gene for the gene products described above.
  • the sequence of the polynucleotides comprised in the deposited strain, as well as the amino acid sequence of any polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.
  • the deposits of the deposited strains have been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure.
  • the deposited strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent.
  • the deposited strains are provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. ⁇ 1 12.
  • a license may be required to make, use or sell the deposited strain, and compounds derived therefrom, and no such license is hereby granted.
  • an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Streptococcus pneumoniae 0100993 strain or Staphylococcus aureus WCUH 29 strain, which polypeptide is comprised in the respective deposited strain.
  • polynucleotide sequences in the deposited strain such as DNA and RNA, and amino acid sequences encoded thereby.
  • polypeptide and polynucleotide sequences isolated from the deposited strain are also provided by the invention.
  • Fab polypeptide of the invention is substantially phylogenetically related to other proteins of the fab family.
  • polypeptides of an organism of the invention particularly streptococci, staphylococci, Escherichia coli or Haemophilus influenzae referred to herein as "fab” and "fab polypeptides” as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.
  • fab polypeptide encoded by naturally occurring alleles of a fab gene are variants of fab polypeptide encoded by naturally occurring alleles of a fab gene.
  • a "fab polypeptide reference sequence” has the sequence of SEQ ID NO: 2, 3, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 or 32 or a corresponding sequence starting from a useful internal initiating codon.
  • the present invention further provides for an isolated polypeptide that: (a) comprises or consists of an amino acid sequence that has at least 95% identity, most preferably at least 97-99% or exact identity, to that of a fab polypeptide reference sequence over the entire length of the fab polypeptide reference sequence; (b) a polypeptide encoded by an isolated polynucleotide comprising or consisting of a polynucleotide sequence that has at least 95% identity, even more preferably at least 97-99% or exact identity to a fab polypeptide reference sequence over the entire length of the fab polypeptide reference sequence; (c) a polypeptide encoded by an isolated polynucleotide comprising or consisting of a polynucleotide sequence encoding a polypeptide that has
  • polypeptides of the invention include a polypeptide of a polypeptide reference sequence (in particular a mature polypeptide) as well as polypeptides and fragments, particularly those that have a biological activity of fab, and also those that have at least 95% identity to a polypeptide of a polypeptide reference sequence and also include portions of such polypeptides with such portion of the polypeptide generally comprising at least 30 amino acids and more preferably at least 50 amino acids.
  • the invention also includes a polypeptide consisting of or comprising a polypeptide of the formula: X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherein, at the amino terminus, X is hydrogen, a metal or any other moiety described herein for modified polypeptides, and at the carboxyl terminus, Y is hydrogen, a metal or any other moiety described herein for modified polypeptides, Ri and R3 are any amino acid residue or modified amino acid residue, m is an integer between 1 and 1000 or zero, n is an integer between 1 and 1000 or zero, and R2 is an amino acid sequence of the invention, particularly an amino acid sequence selected from Table 2 or modified forms thereof. In the formula above, R2 is oriented so that its amino terminal amino acid residue is at the left, covalently bound to
  • R and its carboxy terminal amino acid residue is at the right, covalently bound to R3.
  • Other preferred embodiments of the invention are provided where m is an integer between 1 and 50, 100 or 500, and n is an integer between 1 and 50, 100, or 500.
  • a polypeptide of the invention is derived from streptococci, staphylococci, Escherichia coli or Haemophilus influenzae, however, it can preferably be obtained from other organisms of the same taxonomic genus, or another organism of the invention.
  • a polypeptide of the invention can also be obtained, for example, from organisms of the same taxonomic family or order.
  • a fragment is a variant polypeptide having an amino acid sequence that is entirely the same as part but not all of any amino acid sequence of any polypeptide of the invention.
  • fragments can be "free-standing,” or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region in a single larger polypeptide.
  • Preferred fragments include, for example, truncation polypeptides having a portion of an amino acid sequence of a polypeptide reference sequence or of variants thereof, such as a continuous series of residues that includes an amino- and/or carboxyl-terminal amino acid sequence.
  • Degradation forms of the polypeptides of the invention produced by or in a host cell, particularly a streptococci, staphylococci, Escherichia coli or Haemophilus influenzae are also preferred.
  • fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta- sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.
  • fragments include an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of a fab polypeptide reference sequence, or an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of the fab polypeptide reference sequence.
  • Fragments of the polypeptides of the invention can be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants can be employed as intermediates for producing the full-length polypeptides of the invention.
  • Polynucleotides It is an object of the invention to provide polynucleotides that encode fab polypeptides, particularly polynucleotides that encode a polypeptide herein designated fab.
  • the polynucleotide comprises a region encoding fab polypeptides comprising a sequence set out in a polynucleotide reference sequence that includes a full length gene, or a variant thereof.
  • This invention provides that this full length gene is essential to the growth and/or survival of an organism that possesses it, such as from streptococci, staphylococci, Escherichia coli or Haemophilus influenzae.
  • a "fab polynucleotide reference sequence” has the coding sequence of SEQ ID NO: 1 , 4, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29 or 31 or a corresponding segment thereof from a useful initiation codon up to (but excluding) the stop codon.
  • isolated nucleic acid molecules encoding and/or expressing fab polypeptides and polynucleotides, particularly from an organism of the invention, especially a streptococci, staphylococci, Escherichia coli or Haemophilus influenzae fab polypeptides and polynucleotides, including, for example, unprocessed RNAs, ribozyme RNAs, mRNAs, cDNAs, genomic DNAs, B- and Z-DNAs.
  • Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful polynucleotides and polypeptides, and variants thereof, and compositions comprising the same.
  • Another aspect of the invention relates to isolated polynucleotides, including at least one full length gene, that encodes a fab polypeptide having a deduced amino acid sequence of a polypeptide reference sequence and polynucleotides closely related thereto and variants thereof.
  • a fab polypeptide from an organism of the invention particularly streptococci, staphylococci, Escherichia coli or Haemophilus influenzae comprising or consisting of an amino acid sequence of a polypeptide reference sequence, or a variant thereof.
  • a polynucleotide of the invention encoding fab polypeptide can be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from an organism, particularly bacteria, streptococci, staphylococci, Escherichia coli or Haemophilus influenzae cells as starting material, followed by obtaining a full length clone.
  • a polynucleotide sequence of the invention such as a polynucleotide sequence given in Table 2
  • Clones carrying DNA identical to that of the probe can then be distinguished using stringent hybridization conditions.
  • sequencing is then possible to extend the polynucleotide sequence in both directions to determine a full length gene sequence.
  • sequencing is performed, for example, using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).
  • each fab polynucleotide reference sequence was discovered in a DNA library derived from an organism of the invention, particularly streptococci, staphylococci, Escherichia coli or Haemophilus influenzae.
  • each DNA sequence set out in a fab polynucleotide reference sequence contains an open reading frame encoding a protein having about the number of amino acid residues set forth in a polypeptide reference sequence with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known to those skilled in the art.
  • the polynucleotide of a fab polynucleotide reference sequence encodes a fab polypeptide reference sequence.
  • the present invention provides for an isolated polynucleotide comprising or consisting of: (a) a polynucleotide sequence that has at least 95% identity, even more preferably at least 97-99% or exact identity to a fab polynucleotide reference sequence over the entire length of the fab polynucleotide reference sequence; (b) a polynucleotide sequence encoding a polypeptide that has at least 95% identity, even more preferably at least 97-99% or 100% exact, to the amino acid sequence of a fab polypeptide reference sequence, over the entire length of a fab polynucleotide sequence.
  • a polynucleotide encoding a polypeptide of the present invention can be obtained by a process that comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled or detectable probe consisting of or comprising the sequence of a fab polynucleotide reference sequence or a fragment thereof; and isolating a full-length gene and/or genomic clones comprising said polynucleotide sequence.
  • the invention provides a polynucleotide sequence identical over its entire length to a coding sequence (open reading frame) in a fab polynucleotide reference sequence. Also provided by the invention is a coding sequence for a mature polypeptide or a fragment thereof, by itself as well as a coding sequence for a mature polypeptide or a fragment in reading frame with another coding sequence, such as a sequence encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence.
  • the polynucleotide of the invention can also comprise at least one non-coding sequence, including for example, but not limited to at least one non-coding 5' and 3' sequence, such as the transcribed but non-translated sequences, termination signals (such as rho-dependent and rho-independent termination signals), ribosome binding sites, Kozak sequences, sequences that stabilize mRNA, introns, and polyadenylation signals.
  • the polynucleotide sequence can also comprise additional coding sequence encoding additional amino acids. For example, a marker sequence that facilitates purification of a fused polypeptide can be encoded.
  • the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al, Proc. Natl. Acad. Sci., USA 86: 821-824 (1989), or an HA peptide tag (Wilson et al, Cell 37: 767 (1984), both of that can be useful in purifying polypeptide sequence fused to them.
  • Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.
  • a preferred embodiment of the invention is a polynucleotide of consisting of or comprising nucleotides a fab polynucleotide reference sequence, that encode a fab polypeptide.
  • the invention also includes a polynucleotide consisting of or comprising a polynucleotide of the formula:
  • Rj and R3 are independently any nucleic acid residue or modified nucleic acid residue
  • m is an integer between 1 and 3000 or zero
  • n is an integer between 1 and 3000 or zero
  • R 2 is a nucleic acid sequence or modified nucleic acid sequence of the invention, particularly a nucleic acid sequence selected from Table 2 or a modified nucleic acid sequence thereof.
  • R 2 is oriented so that its 5' end nucleic acid residue is at the left, bound to Ri and its 3' end nucleic acid residue is at the right, bound to R3.
  • Any stretch of nucleic acid residues denoted by either R1 and/or R 2 , where m and/or n is greater than l can be either a heteropolymer or a homopolymer, preferably a heteropolymer.
  • the polynucleotide of the above formula is a closed, circular polynucleotide, that can be a double-stranded polynucleotide wherein the formula shows a first strand to which the second strand is complementary.
  • m and/or n is an integer between 1 and 1000.
  • Other preferred embodiments of the invention are provided where m is an integer between 1 and 50, 100 or 500, and n is an integer between 1 and 50, 100, or 500.
  • a polynucleotide of the invention is derived from an organism of the invention, particularly streptococci, staphylococci, Escherichia coli or Haemophilus influenzae, however, it can preferably be obtained from other organisms of the same taxonomic genus.
  • a polynucleotide of the invention can also be obtained, for example, from organisms of the same taxonomic family or order.
  • polynucleotide encoding a polypeptide encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of an organism of the invention, particularly streptococci, staphylococci, Escherichia coli or Haemophilus influenzae fab having an amino acid sequence set out in a polypeptide reference sequence.
  • polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, polynucleotides interrupted by integrated phage, an integrated insertion sequence, an integrated vector sequence, an integrated transposon sequence, or due to RNA editing or genomic DNA reorganization) together with additional regions, that also can comprise coding and/or non-coding sequences.
  • the invention further relates to variants of the polynucleotides described herein that encode variants of a polypeptide having a deduced amino acid sequence of a polypeptide reference sequence. Fragments of polynucleotides of the invention can be used, for example, to synthesize full-length polynucleotides of the invention.
  • polynucleotides encoding fab variants that have the amino acid sequence of fab polypeptide of a polypeptide reference sequence in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, modified, deleted and/or added, in any combination.
  • Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of fab polypeptide.
  • Preferred isolated polynucleotide embodiments also include polynucleotide fragments, such as a polynucleotide comprising a nucleic acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous nucleic acids from a fab polynucleotide reference sequence, or a polynucleotide comprising a nucleic acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous nucleic acids truncated or deleted from the 5' and/or 3' end of the polynucleotide sequence of a fab polynucleotide reference sequence.
  • polynucleotide fragments such as a polynucleotide comprising a nucleic acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous nucleic acids from a fab polynucleotide reference sequence, or a polynucleotide comprising a nucleic acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous nu
  • polynucleotides that are at least 95% or 97% identical over their entire length to a polynucleotide encoding fab polypeptide having an amino acid sequence set out in a polypeptide reference sequence, and polynucleotides that are complementary to such polynucleotides.
  • Polynucleotides that comprise a region that is at least 95% are especially preferred.
  • those with at least 97% are highly preferred among those with at least 95%, and among these, those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.
  • Preferred embodiments are polynucleotides encoding polypeptides that retain substantially the same biological function or activity as a mature polypeptide encoded by a DNA of a fab polynucleotide reference sequence.
  • polynucleotides that hybridize, particularly under stringent conditions, to fab polynucleotide sequences, such as those polynucleotides in Table 2.
  • the invention further relates to polynucleotides that hybridize to the polynucleotide sequences provided herein.
  • the invention especially relates to polynucleotides that hybridize under stringent conditions to the polynucleotides described herein.
  • a specific example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridization support in O.lx SSC at about 65°C.
  • Hybridization and wash conditions are well known and exemplified in Sambrook, et al, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein. Solution hybridization can also be used with the polynucleotide sequences provided by the invention.
  • the invention also provides a polynucleotide consisting of or comprising a polynucleotide sequence obtained by screening an appropriate library comprising a complete gene for a polynucleotide sequence set forth in a fab polynucleotide reference sequence under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in the fab polynucleotide reference sequence or a fragment thereof; and isolating said polynucleotide sequence.
  • Fragments useful for obtaining such a polynucleotide include, for example, probes and primers fully described elsewhere herein.
  • the polynucleotides of the invention can be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding fab and to isolate cDNA and genomic clones of other genes that have a high identity, particularly high sequence identity, to a fab gene.
  • Such probes generally will comprise at least 15 nucleotide residues or base pairs.
  • such probes will have at least 30 nucleotide residues or base pairs and can have at least 50 nucleotide residues or base pairs.
  • Particularly preferred probes will have at least 20 nucleotide residues or base pairs and will have less than 30 nucleotide residues or base pairs.
  • a coding region of a fab gene can be isolated by screening using a DNA sequence provided in a fab polynucleotide reference sequence to synthesize an oligonucleotide probe.
  • a labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.
  • PCR Nucleic acid amplification
  • PCR Nucleic acid amplification
  • the PCR reaction is then repeated using "nested" primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the selected gene sequence).
  • the products of this reaction can then be analyzed by DNA sequencing and a full-length DNA constructed either by joining the product directly to the existing DNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.
  • polynucleotides and polypeptides of the invention can be employed, for example, as research reagents and materials for discovery of treatments of and diagnostics for diseases, particularly human diseases, as further discussed herein relating to polynucleotide assays.
  • polynucleotides of the invention that are oligonucleotides derived from a sequence of a fab polynucleotide reference sequence can be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.
  • the invention also provides polynucleotides that encode a polypeptide that is a mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to a mature polypeptide (when a mature form has more than one polypeptide chain, for instance).
  • Such sequences can play a role in processing of a protein from precursor to a mature form, can allow protein transport, can lengthen or shorten protein half-life or can facilitate manipulation of a protein for assay or production, among other things.
  • the additional amino acids can be processed away from a mature protein by cellular enzymes.
  • a polynucleotide complementary to it For each and every polynucleotide of the invention there is provided a polynucleotide complementary to it. It is preferred that these complementary polynucleotides are fully complementary to each polynucleotide with which they are complementary.
  • a precursor protein, having a mature form of the polypeptide fused to one or more prosequences can be an inactive form of the polypeptide.
  • inactive precursors When prosequences are removed such inactive precursors generally are activated. Some or all of the prosequences can be removed before activation. Generally, such precursors are called proproteins.
  • the entire polypeptide encoded by an open reading frame is often not required for activity. Accordingly, it has become routine in molecular biology to map the boundaries of the primary structure required for activity with N-terminal and C- terminal deletion experiments. These experiments utilize exonuclease digestion or convenient restriction sites to cleave coding nucleic acid sequence. For example, Promega (Madison, WI) sell an Erase-a-baseTM system that uses Exonuclease III designed to facilitate analysis of the deletion products (protocol available at www.promega.com). The digested endpoints can be repaired (e.g., by ligation to synthetic linkers) to the extent necessary to preserve an open reading frame.
  • nucleic acid of a fab polynucleotide reference sequence readily provides contiguous fragments of a fab polypeptide reference sequence to provide an activity, such as an enzymatic, binding or antibody-inducing activity.
  • Nucleic acid sequences encoding such fragments of a polypeptide reference sequence and variants thereof as described herein are within the invention, as are polypeptides so encoded.
  • portions of the N-terminal and/or C-terminal sequence of a protein can generally be removed without serious consequence to the function of the protein. The amount of sequence that can be removed is often quite substantial.
  • the nucleic acid cutting and deletion methods used for creating such deletion variants are now quite routine.
  • any contiguous fragment of a polypeptide reference sequence which retains at least 20%, preferably at least 50%, of an activity of the polypeptide encoded by the gene for a polypeptide reference sequence is within the invention, as are corresponding fragment which are 70%, 80%, 90%, 95%, 97%, 98% or 99%) identical to such contiguous fragments.
  • the contiguous fragment comprises at least 70% of the amino acid residues of a polypeptide reference sequence, preferably at least 80%, 90% or 95% of the residues.
  • one highly preferred embodiment of the invention encompasses segments of nucleic acid that encode all or part of a Fab Polypeptide reference sequence.
  • the nucleic acid is intended for use with an organism that uses the most standard genetic code, this means that the codons encoding the following amino acids can be substituted from within the groups of trinucleotides defined in the corresponding entry below Table 4:
  • a polynucleotide of the invention can encode a mature protein, a mature protein plus a leader sequence (that can be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, that is a precursor to a proprotein, having a leader sequence and one or more prosequences, that generally are removed during processing steps that produce active and mature forms of the polypeptide.
  • the invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.
  • Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the invention.
  • Recombinant polypeptides of the present invention can be prepared by processes well known to those skilled in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems that comprise a polynucleotide or polynucleotides of the present invention, to host cells that are genetically engineered with such expression systems, and to the production of polypeptides of the invention by recombinant techniques.
  • host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention.
  • Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis, et al, BASIC METHODS LN MOLECULAR BIOLOGY, (1986) and Sambrook, et al, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.
  • bacterial cells such as cells of streptococci, staphylococci, enterococci E. coli, streptomyces, cyanobacteria, Bacillus subtilis, and streptococci, staphylococci, Escherichia coli or Haemophilus influenzae
  • fungal cells such as cells of a yeast, Kluveromyces, Saccharomyces, a basidiomycete, Candida albicans and Aspergillus
  • insect cells such as cells of Drosophila S2 and Spodoptera Sf9
  • animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293, CV-1 and Bowes melanoma cells
  • plant cells such as cells of a gymnosperm or angiosperm.
  • vectors include, among others, chromosomal-, episomal- and virus-derived vectors, for example, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses, picomaviruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.
  • the expression system constructs can comprise control regions that regulate as well as engender expression.
  • any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host can be used for expression in this regard.
  • the appropriate DNA sequence can be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al,
  • secretion signals can be inco ⁇ orated into the expressed polypeptide. These signals can be endogenous to the polypeptide or they can be heterologous signals.
  • Polypeptides of the invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding protein can be employed to regenerate active conformation when the polypeptide is denatured during isolation and/or purification.
  • Bioactive agent(s) may be identified or selected from a variety of sources, for example, cells, cell-free preparations, known or newly synthesized compounds, chemical libraries, and natural product mixtures.
  • Bioactive agents of the invention include, among others, small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide and/or polypeptide of the invention and thereby inhibit or extinguish its activity or expression.
  • Bioactive agents may be a small organic molecule, a peptide, a polypeptide, a closely related protein or antibody that binds the same sites on a binding molecule without inducing kinase-induced activities.
  • Antagonists of the invention further include small molecules that bind to and occupy the binding site of a kinase thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented.
  • small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules.
  • Other antagonists include antisense molecules (see Okano, J. Neurochem. 56: 560 (1991); OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton, FL (1988), for a description of these molecules).
  • Bioactive agents of the invention that are small molecules preferably have a molecular weight below 2,000 daltons, more preferably between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is particularly prefe ⁇ ed that these small molecules are organic molecules.
  • Polypeptides and polynucleotides of the invention can also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures.
  • substrates and ligands can be natural substrates and ligands or can be structural or functional mimetics. See, e.g., Coligan et al,
  • Polypeptides and polynucleotides of the present invention are responsible for many biological functions, including many disease states, in particular the Diseases herein mentioned. It is therefore desirable to devise screening methods to identify compounds that agonize (e.g., stimulate) or that antagonize (e.g., inhibit) the function of the polypeptide or polynucleotide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that agonize or that antagonize the function of a polypeptide or polynucleotide of the invention, as well as related polypeptides and polynucleotides.
  • agonists or antagonists can be employed for therapeutic and prophylactic purposes for such Diseases as herein mentioned.
  • Compounds can be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures.
  • Such agonists and antagonists so-identified can be natural or modified substrates, ligands, receptors, enzymes, etc., as the case can be, of fab polypeptides and polynucleotides; or can be structural or functional mimetics thereof (see Coligan et al., Current Protocols in Immunology l(2):Chapter 5 (1991)).
  • the screening methods can simply measure the binding of a bioactive agent to the polypeptide or polynucleotide, or to cells or membranes bearing the polypeptide or polynucleotide, or a fusion protein of the polypeptide by means of a label directly or indirectly associated with the bioactive agent.
  • the screening method can involve competition with a labeled competitor.
  • these screening methods can test whether the bioactive agent results in a signal generated by activation or inhibition of the polypeptide or polynucleotide, using detection systems appropriate to the cells comprising the polypeptide or polynucleotide.
  • Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the bioactive agent is observed.
  • Constitutively active polypeptide and/or constitutively expressed polypeptides and polynucleotides can be employed in screening methods for inverse agonists, in the absence of an agonist or antagonist, by testing whether the bioactive agent results in inhibition of activation of the polypeptide or polynucleotide, as the case can be.
  • the screening methods can simply comprise the steps of mixing a bioactive agent with a solution comprising a polypeptide or polynucleotide of the present invention, to form a mixture, measuring fab polypeptide and/or polynucleotide activity in the mixture, and comparing the fab polypeptide and/or polynucleotide activity of the mixture to a standard.
  • Fusion proteins such as those made from Fc portion and fab polypeptide, as herein described, can also be used for high-throughput screening assays to identify antagonists of the polypeptide of the present invention, as well as of phylogenetically and and/or functionally related polypeptides (see D. Bennett et al, J Mol Recognition, 8:52-58 (1995); and K. Johanson et al, J Biol Chem, 270(16):9459-9471 (1995)).
  • polypeptides and antibodies that bind to and/or interact with a polypeptide of the present invention can also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and/or polypeptide in cells.
  • an ELISA assay can be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that can inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.
  • the invention also provides a method of screening compounds to identify those that enhance (agonist) or block (antagonist) the action of fab polypeptides or polynucleotides, particularly those compounds that are bacteristatic and/or bactericidal.
  • the method of screening can involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment or component, such as a membrane, cell envelope, cytoplasmic extract or cell wall, or a preparation of any thereof, comprising fab polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that can be a fab agonist or antagonist.
  • the ability of the candidate molecule to agonize or antagonize the fab polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate.
  • Molecules that bind gratuitously, i.e., without inducing the effects of fab polypeptide are most likely to be good antagonists.
  • Molecules that bind well and, as the case can be, increase the rate of product production from substrate, increase signal transduction, or increase chemical channel activity are agonists. Detection of the rate or level of, as the case can be, production of product from substrate, signal transduction, or chemical channel activity can be enhanced by using a reporter system.
  • Reporter systems that can be useful in this regard include but are not limited to colorimetric, labeled substrate converted into product, a reporter gene that is responsive to changes in fab polynucleotide or polypeptide activity, and binding assays known in the art.
  • the fab polypeptides, or polynucleotides encoding the fab polypeptides, of the invention provide Fab enzymes involved in the core cycle of bacterial fatty acid biosynthesis.
  • the Fab polypeptides of the present invention include the full length polypeptides and/or biologically active fragments thereof.
  • the preferred fragments contain the substrate binding site and, more preferably, are of a size which allows for their use in the screening methods of the present invention.
  • Another aspect of this embodiment provides reaction conditions sufficient for the action of enzymes, including Fab enzymes, appropriate for bacterial fatty acid biosynthsesis.
  • Sufficient conditions for bacterial fatty acid biosynthesis can include the addition to the above proteins, acyl ca ⁇ ier protein (ACP), biotinylated-ACP, acyl carrier protein synthase (ACPS) or acyl ACPS (AAS).
  • Incubation conditions such as salt concentrations, pH, stabilizers, and the like are well known in the art for the enzymes, as illustrated in Heath and Rock, J.Biol.Chem. 271, 1833-1836, 1996. It will be recognized that optimal conditions can vary with the mixture of enzymes used. Suitable conditions can be determined by ordinary experimentation.
  • Recombinant ACP is expressed in host bacteria with at least a portion of the ACP containing the 4'-phosphopantetheine prosthetic group.
  • the holoprotein can be isolated from the remainder by standard chromatography techniques, such as chromatography using reverse phase HPLC, gel filtration media and ion exchange media such as DEAE Sepharose.
  • Illustrative ACP sequences are presented above and the E. coli gene for an ACP is described, for example, in GenBank Accession No. M84991.
  • Recombinant ACP can be produced, for example, as described in Jones et al., Biochem. Soc. Trans. 21: 202S-202S, 1993.
  • ACP synthase which adds the prosthetic group to ACP using CoA as the source substrate, can be isolated from a source bacteria (e.g. E. coli) by overexpressing the ACP synthase in E. coli and purifying the overexpressed enzyme by conventional methods.
  • the E. coli ACP synthase gene is described, for example in GenBank Accession No. L14681, and can be recombinantly expressed as described, for example, in Jackowski et al., J Biol Chem, 269(4): 2921-8, 1994.
  • enzyme includes polymorphic variants that are silent mutations naturally found within the microorganism population of a strain or species.
  • the enzymes in the preferred embodiment of the invention are fatty acid biosynthesis enzymes, however there is no intent to limit the invention to these enzymes.
  • fatty acid biosynthesis enzymes (and its equivalent term fatty acid biosynthetases) is intended to include those components of proteins or polypeptides capable of synthesizing fatty acids via the three- carbon intermediate, malonyl CoA.
  • the proteins include acyl carrier protein (ACP), malonyl-CoA:ACP transacylase (i.e., fabD), ⁇ -ketoacyl-ACP synthase III (i.e., fabH), NADPH-dependent ⁇ -ketoacyl-ACP reductase (i.e., fabG), ⁇ -hydroxyacyl-ACP dehydrase (i.e., fabA or fabZ), NADH- or NADPH-dependent enoyl-ACP reductase or enoyl-ACP reductase (i.e., fabl), ⁇ -ketoacyl-ACP synthase I (i.e., fabB ), ⁇ -ketoacyl-ACP synthase II (i.e., fabF), and acetyl CoA-ACP transacetylase.
  • ACP acyl carrier protein
  • fabD malonyl-CoA:
  • the ACP of E. coli and of other organisms contains the prosthetic group 4'-phosphopantetheine, to which the growing fatty acid chain is covalently linked by a thioester bond.
  • the term "enzymes” is art recognized for purposes of this invention and can refer to whole intact enzyme or portions or fragments thereof.
  • the present invention further pertains to a method for identifying an antimicrobial compounds that interact with a mutant Fab polypeptide by contacting the mutant Fab polypeptide with a compound under conditions which allow interaction of the compound with the mutant Fab polypeptide to occur.
  • the presence or absence of interaction of the compound with the mutant Fab polypeptide is detected as an indication of whether the compound is an antimicrobial compound.
  • mutant of a Fab polypeptide is intended to include polypeptides which differ from the Fab polypeptide in an alteration of at least one amino acid residue but retain their ability to be useful within the screening assays of the present invention.
  • the mutant Fab polypeptides of the present invention include the full length mutant Fab polypeptide and/or biologically active fragments thereof.
  • the prefe ⁇ ed fragments contain the substrate binding portion and are of a size which allows for their use in the screening methods of the present invention.
  • a particularly prefe ⁇ ed embodiment of the invention is a screen, which can be a High Throughput Screen (HTS) for biological agents affecting fatty acid biosynthesis.
  • HTS High Throughput Screen
  • Enzymes provided in this embodiment can include, for example, FabD, FabH, FabG, FabZ, Fabl and FabF.
  • Substrates for these enzymes can be provided by a reaction mixture that includes holo-ACP, a bacterial enzymatic pathway comprising two or more of FabD, FabH, FabG, FabZ and Fab I, as well as any substrates (e.g. malonyl CoA) or cofactors required for the operation of the enzymes and, in some embodiments, FabF.
  • a NADH-specific enoyl-ACP reductase is used as the enoyl-ACP reductase, Fabl.
  • Enzymes can be derived from Staphylococcus aureus or Streptococcus pneumoniae, or other bacteria. In certain prefe ⁇ ed aspects Fabl or ACP, are derived from Escherichia coli or Haemophilus influenzae. Enzymes from E.coli, Streptococcus pneumoniae, Staphylococcus aureus or Haemophilus influenzae or other homologues can be used to determine specificity of hits. Human FAS1 or other eukaryotic pathways can form the basis of the selectivity screen.
  • Intermediate substrates in the reacting step can be provided in the screen, wherein the intermediate substrates are not derived from said malonyl CoA and are provided in an amount adapted to maintain such intermediate substrates at a concentration at least approaching the K m of the respective enzyme that acts on the substrate during the assay timeframe.
  • the screen can be used by contacting the reaction mixture with a biological agent, conducting a high throughput measurement of the activity of the enzymatic pathway and determining if the contacting altered the activity of the enzymatic pathway.
  • Measurement of the activity of the enzymatic pathway can involve measurement of the activity of enoyl-ACP reductase, Fabl.
  • Methods of high throughput measurement can include spectrophotometrically measuring the consumption of NADH or providing [ 3 H]NADH as a cofactor to the enzymatic pathway and capturing a radioactive product on a support that provides a scintillant.
  • NADPH in a substantially constant amount such that the NADH consumption by enoyl-ACP reductase (Fabl) can be quantitated accurately and without interference, or an amount effective to reduce NADH consumption by more NADPH-dependent enzymes.
  • An NADPH regenerating enzyme system can be provided to the reacting step of the screen.
  • coli or Haemophilus influenzae as the ⁇ -ketoacyl-ACP synthase III, a malonyl-CoA:ACP transacylase derived from Streptococcus or Staphylococcus, a ⁇ -ketoacyl-ACP synthase III derived from Streptococcus, Staphylococcus, Haemophilus influenzae or Escherichia, a
  • NADPH-dependent ⁇ -ketoacyl-ACP reductase derived from Streptococcus or Staphylococcus NADPH-dependent ⁇ -ketoacyl-ACP reductase derived from Streptococcus or Staphylococcus, a ⁇ -hydroxyacyl-ACP dehydrase derived from Streptococcus or Staphylococcus, and an enoyl-ACP reductase derived from Staphylococcus, Haemophilus influenzae or Escherichia.
  • ⁇ -ketoacyl-ACP synthase II is part of the enzymatic pathway.
  • Figure 2 shows a prefe ⁇ ed configuration for a continuous assay monitoring the oxidation of NADH at Fabl, which is the assay of choice.
  • a prefe ⁇ ed point for measuring flux through the pathway is Fabl.
  • the similarly sized boxes representing each of the enzymes in the pathway reflects a preference for balancing their concentrations so that each is equally rate-limiting. This allows inhibition of any step to be readily detected.
  • Estimation of the basic kinetic parameters for each enzyme can be conducted as is known in the art prior to the assembly of the pathway so that critical substrates and intermediates can be maintained at or below Km levels. Computer simulation of the pathway can be used to make such estimations.
  • S. aureus Fabl utilizes both NADH and NADPH as substrates
  • E. coli enzyme which is specific for NADH
  • An NADPH-regenerating system involving glucose and a large excess of glucose 6-phosphate dehydrogenase is proposed to prevent its utilization from interfering with the detection of the signal from NADH.
  • FabF is downstream from Fabl, inhibitors of FabF would most likely go undetected, even in the context of a cyclical pathway. Elimination of FabF converts the partially linear, partially cyclical pathway to a simple linear pathway that can simplify assay configuration, and limit the number of potential intermediates, which can be produced as a result of multiple turns of the cycle.
  • a separate HTS for FabF using a coupled, spectrophotometric assay through FabG can be conducted.
  • Radiolabel is inco ⁇ orated into the acyl group from NADPH] through the action of Fabl.
  • the radiolabeled, biotinylated acyl-ACP is then captured and detected with streptavidin- coated SPA beads.
  • the pathway is made linear by the omission of FabF in order to produce a single, distinct product for detection.
  • E. coli or Haemophilus influenzae Fabl is also used in a preferred aspect of this assay. Care is taken to assure through controls that no isotope effect significantly affects the assay.
  • the screen can include, when a bioactive agent affecting the enzymatic pathway is identified, applying one or more deconvolution assays for determining which enzymes in the enzyme pathway are affected.
  • deconvolution assays comprise contacting the identified bioactive agent with (i) an enzyme in the enzymatic pathway or (ii) two or more, but less than all, enzymes acting sequentially in the enzymatic pathway.
  • Deconvolution of primary hits can be conducted without the need for screening all hits against each of the component enzymes.
  • Quantitation of reaction intermediates can be done, for example, using mass spectroscopy, or quantitation of acyl-ACPs after separation using conformationally-sensitive gel electrophoresis.
  • Assays for individual enzymes in the pathway will be set up for follow-up and mechanistic analysis. Potential configurations for these are listed below. Note that in all the assays of the invention, including those detailed below, acyl-CoA is substituted for acyl-ACP.
  • Radiolabeled acetoacetyl-ACP is detected via TCA precipitation or by streptavidin-SPA using biotinylated holo-ACP as the starting substrate.
  • the assay can use acyl- CoA instead of acyl-ACP.
  • FabH Assayed by: 1.
  • FabG Assayed by: 1. A spectrophotometric assay that continuously monitors the consumption of NADP; or
  • FabZ Assayed by: 1. A continuous spectrophotometric assay (NADH consumption) coupled through Fabl to monitor production of crotonoyl ACP, or
  • NAD[ 3 H] as a substrate, monitor the production of radiolabeled butyryl-ACP either via TCA precipitation or by streptavidin-SPA using biotinylated crotonoyl-ACP as the starting substrate.
  • Radiolabeled 3-hydroxyhexanoyl-ACP is detected either via TCA precipitation or by streptavidin-SPA using biotinylated butyryl-ACP as the starting substrate, or
  • the screen can comprise a reaction mixture including (a) holo-ACP or 14 C- malonyl-CoA, (b) malonyl CoA, (c) a bacterial enzymatic pathway comprising (i) malonyl-CoA:ACP transacylase, (ii) ⁇ -ketoacyl-ACP synthase III, (iii) NADPH-dependent ⁇ -ketoacyl-ACP reductase, (iv) ⁇ -hydroxyacyl-ACP dehydrase and (v) enoyl-ACP reductase and (d) the cofactors required for the operation of the enzymes; contacting the reaction mixture with the reaction mixture; conducting a measurement of the activity of the enzymatic pathway; and determining if the contacting altered the activity of the enzymatic pathway, wherein at least one of the following applies: (1) the
  • the present invention provides methods of treating abnormal conditions such as, for instance, a Disease, related to either an excess of, an under-expression of, an elevated activity of, or a decreased activity of fab polypeptide and/or polynucleotide.
  • One approach comprises administering to an individual in need thereof an inhibitor compound (antagonist) as herein described, optionally in combination with a pharmaceutically acceptable carrier, in an amount effective to inhibit the function and/or expression of the polypeptide and/or polynucleotide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition.
  • an inhibitor compound as herein described
  • a pharmaceutically acceptable carrier in an amount effective to inhibit the function and/or expression of the polypeptide and/or polynucleotide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition.
  • soluble forms of the polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide and/or polynucleotide can be administered.
  • Typical examples of such competitors include fragments of the fab polypeptide and/or polypeptide.
  • Each of the polynucleotide sequences provided herein can be used in the discovery and development of antibacterial compounds.
  • the encoded protein upon expression, can be used as a target for the screening of antibacterial drugs.
  • the polynucleotide sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.
  • the invention also provides the use of the polypeptide, polynucleotide, agonist or antagonist of the invention to interfere with the initial physical interaction between a pathogen or pathogens and a eukaryotic, preferably mammalian, host responsible for sequelae of infection.
  • the molecules of the invention can be used: in the prevention of adhesion of bacteria, in particular gram positive and/or gram negative bacteria, to eukaryotic, preferably mammalian, extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block bacterial adhesion between eukaryotic, preferably mammalian, extracellular matrix proteins and bacterial fab proteins that mediate tissue damage and/or; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.
  • fab agonists and antagonists preferably bacteristatic or bactericidal agonists and antagonists.
  • antagonists and agonists of the invention can be employed, for instance, to prevent, inhibit and/or treat diseases.
  • Antagonists of the invention include, among others, small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide and/or polypeptide of the invention and thereby inhibit or extinguish its activity or expression.
  • Antagonists also can be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing fab- induced activities, thereby preventing the action or expression of fab polypeptides and/or polynucleotides by excluding fab polypeptides and/or polynucleotides from binding.
  • Antagonists of the invention also include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented.
  • small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules.
  • Other antagonists include antisense molecules (see Okano, J. Neurochem. 56: 560 (1991); OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton, FL (1988), for a description of these molecules).
  • Prefe ⁇ ed antagonists include compounds related to and variants of fab.
  • polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case can be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.
  • Small molecules of the invention preferably have a molecular weight below 2,000 daltons, more preferably between 300 and 1 ,000 daltons, and most preferably between 400 and 700 daltons. It is preferred that these small molecules are organic molecules.
  • acyl carrier moiety is a substance effective to cany the acyl moiety which are acted upon as intermediates towards the biosynthesis of fatty acids in the fatty acid synthesis pathway relevant to the invention. Examples include: (1) holo-ACP; or (2) apoACP, CoA and acyl carrier protein synthase (ACPS) or acyl ACPS (AAS); and (3) acyl-CoA.
  • bioactive agent is a substance such as a chemical that can act on a cell, virus, tissue, organ or organism, including but not limited to insecticides or drugs (i.e., pharmaceuticals) to create a change in the functioning of the cell, virus, organ or organism.
  • the organism is a mammal, more preferably a human.
  • methods of identifying bioactive agents of the invention are applied to organic molecules having molecular weight of about 1500 or less.
  • Cofactors are ancillary substrates (i.e., substrates that do not provide carbon to the product of an enzyme or enzymatic pathway) such as NADH or are reagents that provide enzyme conditions that are favorable to the enzyme-catalyzed reaction, such as reaction-facilitating salts or buffering agents.
  • enzyme naming The enzymes used herein are often refe ⁇ ed to by certain gene names, such as fabD, fabH, and the like. When the gene name is used herein it should be understood that, except for prefe ⁇ ed embodiments, what is referred to is any microbial enzyme having the co ⁇ esponding enzymatic activity. Known correspondences include the following:
  • a high throughput measurement is a measurement of enzyme activity that can be taken in situ in the reaction mixture, without chemical separation, including separation of a solid phase from a liquid phase.
  • intermediate substrates are substances produced by one step of an enzymatic pathway that are used in a subsequent step.
  • NADPH regenerating enzyme system is at least one enzyme and at least one substrate therefor effective to convert NADP + to NADPH.
  • An example of a NADPH regenerating enzyme system is glucose-6-phosphate dehydrogenase, hexokinase, ATP, and glucose.
  • Disease(s) means any disease caused by or related to infection by a bacteria, including, for example, disease, such as, infections of the upper respiratory tract (e.g., otitis media, bacterial tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal (e.g., secretory dia ⁇ hoea, splenic abscesses, retroperitoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis, darcryocystitis), kidney and urinary tract (e.g., epididymitis, intrarenal and perinephric abscesses, toxic shock syndrome), skin (e.g., impetigo, follicu
  • Host cell(s) is a cell that has been introduced (e.g., transformed or transfected) or is capable of introduction (e.g., transformation or transfection) by an exogenous polynucleotide sequence.
  • Identity is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case can be, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case can be, as determined by the match between strings of such sequences.
  • Identity can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M.
  • Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs. Computer program methods to determine identity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Altschul, S.F. et al., J. Molec. Biol. 215: 403-410 (1990).
  • the BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990).
  • the well known Smith Waterman algorithm can also be used to determine identity.
  • Parameters for polypeptide sequence comparison include the following: Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970) Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89: 10915-10919 (1992) Gap Penalty: 12 Gap Length Penalty: 4 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).
  • Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 95, 97 or 100% identity to the reference sequence of a fab polynucleotide reference sequence, wherein said polynucleotide sequence can be identical to the reference sequence of the fab polynucleotide reference sequence or can include up to a certain integer number of nucleotide alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations can occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in a fab polynucle
  • Polypeptide embodiments further include an isolated polypeptide comprising a polypeptide having at least a 95, 97 or 100% identity to a polypeptide reference sequence of a polypeptide reference sequence, wherein said polypeptide sequence can be identical to the reference sequence of a polypeptide reference sequence or can include up to a certain integer number of amino acid alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations can occur at the amino- or carboxy- terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of amino acid alterations is determined by multiplying the total number of amino acids in a polypeptide reference sequence by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in a polypeptide reference sequence, or: n
  • Individual(s) means a multicellular eukaryote, including, but not limited to a metazoan, a mammal, an ovid, a bovid, a simian, a primate, and a human.
  • Isolated means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both.
  • a polynucleotide or a polypeptide naturally present in a living organism is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.
  • a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated” even if it is still present in said organism, which organism can be living or non-living.
  • Organism(s) means a (i) prokaryote, including but not limited to, a member of the genus Streptococcus, Staphylococcus, Bordetella, Corynebacterium, Mycobacterium, Neisseria, Haemophilus, Actinomycetes, Streptomycetes, Nocardia, Enterobacter, Yersinia, Fancisella, Pasturella, Moraxella, Acinetobacter, Erysipelothrix, Branhamella, Actinobacillus, Streptobacillus, Listeria, Calymmatobacterium, Brucella, Bacillus, Clostridium, Treponema, Escherichia, Salmonella, Kleibsiella, Vibrio, Proteus, Erwinia, Borrelia, Leptospira, Spirillum, Campylobacter, Shigella, Legionella, Pseudomonas, Aeromonas, Ricke
  • Polypeptide(s) refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds.
  • Polypeptide(s) refers to both short chains, commonly refe ⁇ ed to as peptides, oligopeptides and oligomers and to longer chains generally refe ⁇ ed to as proteins. Polypeptides can comprise amino acids other than the 20 gene encoded amino acids.
  • Polypeptide(s) include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art.
  • a given polypeptide can comprise many types of modifications. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini.
  • Modifications include, for example, acetylation, acylation, ADP- ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP- ribosylation, seleno
  • Polypeptides can be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides can result from post-translational natural processes and can be made by entirely synthetic methods, as well.
  • Recombinant expression system(s) refers to expression systems or portions thereof or polynucleotides of the invention introduced or transformed into a host cell or host cell lysate for the production of the polynucleotides and polypeptides of the invention.
  • Variant(s) is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide.
  • Changes in the nucleotide sequence of the variant can or can not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes can result in amino acid substitutions, additions, deletions, fusion proteins and truncations in the polypeptide encoded by the reference sequence, as discussed below.
  • a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
  • a variant and reference polypeptide can differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
  • a substituted or inserted amino acid residue can or can not be one encoded by the genetic code.
  • the present invention also includes include variants of each of the polypeptides of the invention, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and lie; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gin; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly prefe ⁇ ed are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.
  • a variant of a polynucleotide or polypeptide can be a naturally occurring such as an allelic variant, or it can be a variant that is not known to occur naturally.
  • Non-naturally occu ⁇ ing variants of polynucleotides and polypeptides can be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.
  • Other Aspects The nucleic acid sequences described herein, and consequently the protein sequences derived therefrom, have been carefully sequenced. However, those of ordinary skill will recognize that nucleic acid sequencing technology can be susceptible to inadvertent error.
  • sequences recited in the Sequence Listing as "DNA" represent an exemplification of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including ribopolynucleotides.
  • Example 1 Sequence of E. coli Acyl Carrier Protein
  • the sequence of the E. coli apo-ACP we have cloned and overexpressed is the same one originally described by Rawlings and Cronan (Rawlings, M. and Cronan, J.E., Jr. [1992] J. Biol. Chem. 267, 5751-5754).
  • the nucleotide and protein sequences are given below: Nucleotide sequence of E. coli ACP .
  • acyl- ACP's are variants of holo-ACP in which the phosphopantetheinyl group is conjugated with various acyl groups as defined below.
  • Holo-ACP itself is a derivative of apo-ACP, the starting material in our syntheses, where Ser 37 (highlighted above) is conjugated to the phosphopantetheinyl moiety of coenzyme A.
  • Ser 37 (highlighted above) is conjugated to the phosphopantetheinyl moiety of coenzyme A.
  • Table 1 Example 3 - Expression and Purification of E. coli apo-ACP
  • E. coli apo-ACP was over expressed in an E. coli expression system.
  • the cell pellet was suspended in 10 volumes of 20 mM Tris HCl, 0.1 M NaCl, 5 mM MgCl 2 , 2 mM MnCl 2 , pH 7.0.
  • the pH and temperature were raised to 8.5 and 35 °C, respectively. These conditions were maintained for 2 hours by intermittently adjusting the pH with NaOH. Following this, the pH was adjusted to 7.0 with HC1, and an equal volume of isopropyl alcohol was added with stirring. Stirring was continued at 4 °C overnight.
  • the apo-ACP was eluted with the following gradient: Buffer A: 20 mM Bis-Tris, pH 6.8; Buffer B: 1 M NaCl in 20 mM Bis-Tris, pH 6.8; at a flow rate of 20 mL/minute, at: Time: 0 15 110 1 1 1 126 127 130 %B : 20 20 60 100 100 20 20
  • Buffer A was comprised of 20 mM Tris HCl, pH 7.4; Buffer B was comprised of 20 mM Tris-HCl, pH 7.4, IM NaCl. All chromatography was run at a constant flow rate of 1 mL/minute. Samples were loaded onto a Pharmacia Mono Q (5/5) column equilibrated with Buffer A. The column was washed for 5 minutes with 10% Buffer B, and the ACP's or acyl-ACP's were eluted during an 0.5%/minute linear gradient to 50% Buffer B. ACP standards eluted as follows: apo-ACP (34% B), holo-ACP (37% B), malonyl-ACP (39% B). The column was washed with 5 mL 100% Buffer B prior to equilibration with Buffer A.
  • Holo-ACP was synthesized via the ACP synthase reaction containing 0.1 M NaHEPES, pH 7.5, 0.1 mM apo-ACP, 0.15 mM CoA, 1 mM DTT, 10 mM MgCl 2 , 60 ⁇ g/mL ACPS (S. pneumoniae or E. coli). Holo-ACP synthesis was confirmed by FPLC and functionally as a substrate for the FabD reaction either by monitoring the inco ⁇ oration of [ l4 C]malonyl-CoA into malonyl-ACP or via the FabD:FabH coupled enzyme assay by monitoring the inco ⁇ oration of [ 3 H]acetyl-CoA into acetoacetyl-ACP.
  • Example 6 Synthesis of Acetyl-ACP
  • Acetyl-ACP was synthesized via the ACP synthase reaction which contained 0.1 M NaHEPES, pH 7.5, 10 mM MgCl 2 , 0.2 mM acetyl-CoA, 0.1 mM apo-ACP, and 60 ⁇ g/mL E. coli or S. pneumoniae ACP synthase. Reaction volumes ranged up to 100 L. Approximately 95-100% conversion of apo-ACP to acetyl-ACP was achieved within a 1-hour incubation at 33 °C as demonstrated by FPLC, which showed the disappearance of the apo-ACP substrate and emergence of a new product peak.
  • acetyl-ACP was quantitated by measuring its absorbance at 280 nm. Although acetyl-ACP is not a currently recognized intermediate of fatty acid biosynthesis, it was found to be an inhibitor of FabH through the formation of dead end inhibition complexes with enzyme.
  • Example 7 Synthesis of Malonyl-ACP via FabD (Acyl-CoA:ACP(holo) Transacylase)
  • reaction conditions required 0. IM Na phosphate, pH 7.0, 1 mM TCEP, malonyl-CoA:holo-ACP (50: 1 ; respectively), and 250 nM FabD. This reaction was placed over an Ni-NTA agarose spin column (Qiagen) to remove the His-tagged FabD.
  • the ACP's were separated from the reducing agent through a PD-10 column equilibrated with 100 mM Na phosphate, pH 7.0; the protein from the column effluent was place over a 1-mL spin-column of activated thiol-Sepharose 4B (Pharmacia) equilibrated in 100 mM Na phosphate, pH 7.0 to remove contaminating holo- ACP and CoA. Malonyl-ACP was concentrated via centrifugation in an Amicon
  • Reaction mixtures contained 0.1 M NaHEPES, pH 7.5, 10 mM MgCl 2 , 0.5 mM malonyl-CoA, 0.3 mM apo-ACP, and 40-60 ⁇ g/mL E. coli ACP synthase.
  • the progress of the reaction was monitored by FPLC, and approximately 95-100% conversion of the apoACP to malonyl-ACP was achieved within a 2-hour reaction at 33 °C.
  • Example 9 Synthesis of Acetoacetyl-ACP
  • E. coli apo-ACP (4.1 g), E. coli ACP synthase (40 mg) and buffer composed of 20 mM Bis-Tris, pH 6.8, 63 mM NaCl and 13 mM MgCl 2 (total volume 240 mL) were combined in a sti ⁇ ed reaction vessel and incubated at 22 °C.
  • Acetoacetyl-CoA (15 mM in 20 mM Bis-Tris, pH 6.8) was added incrementally in 8-mL (125-mg) aliquots over a 1-hour period until a total of 1 g had been added. Incubation was continued while maintaining the pH at 6.8 by the addition of 6 N HCl.
  • This reagent was synthesized from malonyl-ACP in a coupled enzyme system consisting of 20 mM Bis-Tris, pH 6.8, 50 mM NaCl, 2 mM DTT, 100 mg (0.5 mM) malonyl-ACP, 1.5 mM acetyl-CoA, 1 mM NADPH, 70 nM S. pneumoniae FabH and 300 nM S. pneumoniae FabG in a total volume of approximately 25 mL.
  • the reaction was initiated by the addition of the FabH, and continued for 4 hours at 22 °C while maintaining the pH at 6.8 by the addition of 6 N HCl.
  • Butyryl-ACP was synthesized in reaction mixtures containing 0.1 M NaHEPES, pH 7.5, 10 mM MgCl 2 , 0.2 mM butyryl-CoA, 0.1 mM apo-ACP, and 20 ⁇ g/mL E. coli ACP synthase in total volumes up to 50 mL. Approximately 95-100% conversion of apo-ACP to butyryl-ACP was achieved within 1 hour at 33 °C as demonstrated by FPLC, which showed the disappearance of the apo-ACP substrate and emergence of a new product peak.
  • butyryl-ACP was quantitated by either measuring its absorbance at 280 nm or in a functional assay utilizing malonyl-ACP and a FabF/FabG coupled, spectrophotometric assay measuring the disappearance of NADPH at 340 nm.
  • Example 13 - FabD Assay Filtration assay [ 14 C]Malonyl-ACP formation was specifically measured using [ I4 C]malonyl-CoA and holo-ACP.
  • the substrate [ 14 C]malonyl-CoA is soluble in 10% TCA while the resulting [ 14 C]malonyl-ACP is not.
  • Final reaction conditions typically were 100 mM NaP0 4 , pH 7.0, 1 mM DTT, 50 ⁇ M malonyl-CoA, 8 ⁇ M [ 14 C]malonyl-CoA (specific activity 56 mCi/mmol), and 25 ⁇ M E. coli holo-ACP.
  • the enzyme S.
  • a product of the malonyl-CoA:ACP transacylase reaction is free coenzyme A. This fact was exploited by coupling the FabD reaction with an excess of ⁇ -ketoglutarate dehydrogenase (Sigma).
  • Reaction mixtures typically contained lOOmM NaP0 4 , pH 7.0, 1 mM DTT, 0.5 M NAD + , 1 mM ⁇ -ketoglutaric acid, 0.5 mU/ ⁇ l ⁇ -ketoglutarate dehydrogenase, 50 ⁇ M malonyl-CoA, 25 ⁇ M E. coli holo-ACP and InM S. aureus FabD. NAD + reduction was followed spectroscopically at 340 nm.
  • assay followed the inco ⁇ oration of [ 3 H]acetyl-CoA into the TCA-precipitable [ 3 H]acetoacetyl-ACP.
  • assay mixtures contained either fixed (50 ⁇ M [ H-]acetyl- CoA and 20 ⁇ M malonyl-ACP) or variable concentrations of substrate and were initiated by the addition of FabH.
  • Incubations were ca ⁇ ied out in temperature equilibrated (33°C) reaction microcentrifuge tubes or Falcon 3077 96-well reaction plates, and incubated for the stated amount of time.
  • Reactions were terminated either by adding sample aliquots from reaction tubes into 3 mL 10% TCA with the addition of 0.2 mg BSA, or by adding 0.15 mL 10% TCA and 0.1 mg BSA directly into the reaction plate. Quenched reaction plates were chilled for 20 minutes prior to filtration. Precipitated proteins were recovered from tubes by filtration through Whatman GF/C filter discs with three rinses of 10% TCA, and a final rinse of with 3 mL 1 % TCA. The filters were dried and counted in 8 mL Beckman ReadySafe and counted in a Beckman LS6500.
  • Precipitated proteins in reaction plates were recovered by filtration through Packard GF/C Unifilters with a Packard Filtermate with three rinses of the reaction plate with 10% TCA and a final rinse with 1 % TCA. Plates were dried, sealed and counted with 30 ⁇ L Microscint 0 per well in a Packard TopCount scintillation counter.
  • Example 15 - FabH Coupled Assay The FabH/FabG coupled assay was done in Costar 384-well plates. A reaction mixture consisting of malonyl-ACP (15 ⁇ M), acetyl-CoA (20 ⁇ M), NADPH (100 ⁇ M) and S.
  • pneumoniae FabG (0.15 ⁇ M) was prepared in 100 mM NaP0 4 , pH 7.0 containing 1 mM TCEP. To the plate was added 1 ⁇ L of compound in DMSO solution followed by the reaction mixture (44 ⁇ L). The plate containing the reaction mixture and the compound was incubated at 33 °C for 5 minutes while H. influenzae FabH was incubated separately at the same temperature. The reaction was started by adding 5 ⁇ L of FabH (0.008 ⁇ M final concentration) to the reaction wells, mixing and reading the plate at 340 nm in Spectromax Plus 384 plate reader set at 33 °C. Data was collected over 15 minutes.
  • Example 16 - FabG Screening Assay The FabG assay was run in clear 384-well (Falcon 3902) plates in a total volume of 50 ⁇ L. Reaction mixtures contained 100 mM NaHEPES, pH 7.5, 50 ⁇ M NADPH, 25 ⁇ M acetoacetyl-ACP, and 80 nM S. pneumoniae FabG. The NADPH was preincubated with the FabG for 15 minutes prior to their addition to the assay plate in order to generate and stabilize the active form of the enzyme. After initiation, incubations were ca ⁇ ied out for 5 minutes at 30 °C while monitoring the decrease in absorbance at 340 nm using a Tecan Spectroflour PLUS TM plate reader. Example 17 - FabG Screening Data
  • the assay was performed in 384 well plates using Tecan Spectrofluore to measure the absorbance using a 340nm filter. The final volume of the assay was 50 ⁇ l and the reagents were prepared 5x concentrated so that lO ⁇ l of each reagent was added to the wells. To the wells was added buffer (lOOmM HEPES, pH 7.5), NADH ( lOOuM), fabl (200nM, diluted in 20% glycerol) and fabZ (9.2nM). The plate was incubated in a heating block at 30°C for 5-10 minutes.
  • the substrate 3-OH-butyryl-ACP was diluted in 20mM bis-Tris buffer, pH 6.5 and incubated at 30°C as well.
  • the reaction was started by adding 3-OH-butyryl-ACP to the reaction wells, mixing and reading the plate at 340nm.
  • the final concentration of HEPES was 80mM and bis-Tris was 4mM.
  • blanks were prepared using 40 ⁇ l buffer and NADH (lOO ⁇ M).
  • Assays were ca ⁇ ied out in 96-well half-area plates in a total volume of 50 ⁇ L in a FabG coupled system containing 100 M NaP0 4 , pH 7.0, 100 ⁇ M NADPH, 10 ⁇ M malonyl-ACP, 10 ⁇ M butyryl-ACP, and 600 nM S. pneumoniae FabG. Compounds were added to the above mixture at a final concentration of 2 and 20 ⁇ M and mixed for 30 seconds on a plate shaker prior to running the assay. The reaction was started by the addition of 100 nM (final concentration) Streptococcus pneumoniae FabF.
  • the S.pneumoniae fabK, enoyl-ACP reductase gene was PCR amplified from S.pneumoniae strain 0100993.
  • the forward and reverse primer sequences were 5 ' AGGTTGGAGGCCATATGAAAACGCGTATT 3 ' [SEQ ID NO:35] and
  • Fractions containing FabK were identified by their absorbance at A460 and by their FabK activity and pooled. 1.5 M ammonium sulphate was added to the pooled fractions and these were then loaded onto a Hi-load Phenyl sepharose (16/10) column (Pharmacia) equilibrated in 50 mM Tris pH 7.5, 1 mM PMSF, 1 mM Benzamidine, 1 mM DTT, 1.5 M ammonium sulphate. Proteins were eluted with a gradient of ammonium sulphate (1.5 to 0 M) over 200 ml. Fractions containing FabK were identified as above and pooled.
  • the pooled fractions were buffer exchanged into 100 mM Tris, pH 7.5, 2 mM DTT and glycerol was then added to 50%.
  • the protein was stored at -20°C. It is preferred that the enzyme be stored with NH C1, which has been found to stabilize the enzyme.
  • the identity of the protein was confirmed by N-terminal sequencing and MALDI mass spectrometry.
  • the optical spectrum of the protein was characteristic of flavoproteins, showing an absorbance in the 450 nm region.
  • the FAD cofactor was removed by denaturation of the protein and quantified.
  • the ratio of FAD:protein was shown to be approximately 1 :1.
  • FabK catalyses the reduction of enoyl-ACPs with the concommitant oxidation of NADH.
  • Crotonoyl-ACP can be prepared as described below. The reduction of crotonoyl- ACP to butyryl-ACP can be monitored by following the change in absorbance at 340 nm as NADH is oxidised. Assays were ca ⁇ ied out in Costar 3696 half-area plates in a final assay volume of 150 ⁇ l on a Spectramax platereader.
  • Crotonoyl -ACP was synthesised using S. pneumoniae ACP synthase to catalyse the addition of a crotonoyl group from crotonoyl CoA to E.coli apo-acyl ca ⁇ ier protein (ACP).
  • ACP E.coli apo-acyl ca ⁇ ier protein
  • the pH of the reaction was maintained at 6.8 with NaOH and monitored for completion by mass spectrometry. Conversion was complete within 150 minutes with no detectable by-products.
  • the reaction mixture was loaded at 10 mL/minute onto a Q- Sepharose FF column (5 x 16 cm) pre-equilibrated with 20 mM Bis-Tris, pH 6.8.
  • Crotonoyl-ACP was eluted over 2200 ml using a 0.2M-0.6M NaCl gradient at a flow rate of 20 ml/minute. Fractions were monitored by mass spectrometry for identity and purity. The appropriate fractions were pooled and concentrated using a YM-3 membrane.
  • Example 28 - Fabl Assay Method Fabl enzyme, and methods of making and using it, is disclosed in patent applications numbered PCT/US00/12104 and EPl 997000306506.
  • Crotonoyl-ACP can be prepared as described in patent applications numbered PCT/US00/12104 and EPl 997000306506. The reduction of enoyl-ACPs can be monitored by following the change in absorbance at 340 nm as NADH is oxidised.
  • Enoyl ACPs eg., crotonoyl-ACP
  • enoyl-CoAs e.g., crotonoyl-CoA
  • This assaying can also be performed using crotonyl CoA, NADPH or an NADH analogue as a substrate, or using a substrate suitable for FabK, such as those described above.
  • compounds can be tested for inhibition of Fabl.
  • 30 ul of a bioactive agents is added to a well of the plate.
  • 30 ⁇ l of a 250 uM stock of NADH is then added to the well.
  • 60 ⁇ l of a 67.5 uM stock of Crotonoyl ACP is added to the well.
  • the plate is incubated at 30°C for 5 minutes.
  • 30 ⁇ l of a 6.25 nM stock of enzyme is then added to the well (also preincubated at 30°C) to initiate the reaction.
  • the plate is then monitored at A340nm for 30 minutes at 30°C.
  • Positive controls are reactions without compound.
  • Negative controls are reactions without enzyme and without compound.
  • Final concentrations in the assay mixture are 25 ⁇ M crotonoyl ACP and 50 ⁇ M NADH.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne un procédé de criblage de composés influant sur la biosynthèse d'acides gras, le procédé consistant en ce qui suit: (A) fournir un mélange de réaction comprenant: (1) (a) un groupe fonctionnel transporteur d'enzymes ou (b) des enzymes ou précurseurs suffisants pour générer un groupe fonctionnel transporteur d'enzymes; (2) une voie de signalisation bactérienne enzymatique comprenant au moins deux (et de préférence trois, voire quatre ou cinq) enzymes agissant de manière consécutive, sélectionnée dans le groupe constitué de: (a) malonyl-CoA:ACP transacylase, (b) β-kétoacyl-ACP synthase III, (c) β-kétoacyl-ACP réductase dépendant de NADPH, (d) β-hydroxyacyl-ACP déhydrase et (e) enoyl-ACP réductase; et (3) des substrats et cofacteurs nécessaires au fonctionnement des enzymes; (B) mettre en contact le mélange de réaction avec un agent biologique prospecté; (C) effectuer des mesures haut débit de l'activité de la voie de signalisation enzymatique; et (D) déterminer si la mise en contact a modifié l'activité de la voie de signalisation enzymatique. L'invention concerne aussi un procédé de dosage des composés influençant la biosynthèse d'acides gras, qui consiste en ce qui suit: (A) fournir un mélange de réaction comprenant: (1) (a) un groupe fonctionnel transporteur d'acyles ou (b) des enzymes et précurseurs suffisant pour générer le groupe fonctionnel transporteur d'acyles; (2) une voie de signalisation bactérienne enzymatique comprenant au moins deux enzymes agissant de manière consécutive, sélectionnée dans le groupe constitué de: (a) malonyl-CoA:ACP transacylase, (b) β-kétoacyl-ACP synthase III, (c) β-kétoacyl-ACP réductase dépendant de NADPH, (d) β-hydroxyacyl-ACP déhydrase et (e) enoyl-ACP réductase; et (3) des substrats et cofacteurs nécessaires pour le fonctionnement des enzymes; (B) mettre en contact le mélange de réaction avec un agent biologique prospecté; (C) effectuer des mesures haut débit de l'activité de la voie de signalisation enzymatique; et (D) déterminer si la mise en contact a modifié l'activité de la voie de signalisation enzymatique, pourvu qu'au moins ce qui suit soit valable: (1) la réductase enoyl-ACP est une réductase enoyl-ACP spécifique au NADH; ou (2) la β-kétoacyl-ACP synthase III et une β-kétoacyl-ACP synthase III dérivée de E.coli ou H. influenzae; ou (3) NADPH est fourni au stade de réaction de façon constante de manière à ce que la consommation de NADH par enoyl-ACP réductase (FabI) peut être quantifiée avec précision et sans interférence, ou une quantité efficace pour réduire la consommation de NADH par des enzymes plus dépendantes de NADPH; ou (4) la β-kétoacyl-ACP réductase dépendant de NADPH est dérivée de Streptococcus, Staphylococcus or Pseudomonas.
PCT/US2000/029451 1999-10-27 2000-10-26 Procedes de fabrication et d'utilisation de reactifs de voies de synthese d'acides gras WO2001030988A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/089,019 US6951729B1 (en) 1999-10-27 2000-10-26 High throughput screening method for biological agents affecting fatty acid biosynthesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16177599P 1999-10-27 1999-10-27
US60/161,775 1999-10-27

Publications (2)

Publication Number Publication Date
WO2001030988A1 true WO2001030988A1 (fr) 2001-05-03
WO2001030988A8 WO2001030988A8 (fr) 2001-09-07

Family

ID=22582667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029451 WO2001030988A1 (fr) 1999-10-27 2000-10-26 Procedes de fabrication et d'utilisation de reactifs de voies de synthese d'acides gras

Country Status (1)

Country Link
WO (1) WO2001030988A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178820A1 (fr) * 1999-05-06 2002-02-13 SmithKline Beecham Corporation Procedes de modulation de l'activite de fabh
US6753172B1 (en) 1996-08-28 2004-06-22 Affinium Pharmaceuticals, Inc. FabI
US6821746B2 (en) 2000-10-06 2004-11-23 Affinium Pharmaceuticals, Inc. Methods of screening for FabK antagonists and agonists
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
US7033795B2 (en) 2000-10-06 2006-04-25 Affinium Pharmaceuticals, Inc. FabK variant
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
US7056697B2 (en) 2000-10-06 2006-06-06 Affinium Pharmaceuticals, Inc. FabK variant
US7176299B2 (en) 1996-02-20 2007-02-13 Affinium Pharmaceuticals, Inc. Compounds
US7250285B2 (en) 1996-08-16 2007-07-31 Affinium Pharmaceuticals, Inc. Purified polypeptides from Streptococcus pneumoniae
US7799547B2 (en) 2003-07-11 2010-09-21 Affinium Pharmaceuticals, Inc. Purified polypeptides from Staphylococcus aureus
WO2015200335A1 (fr) * 2014-06-23 2015-12-30 Joule Unlimited Technologies, Inc. Microbes photosynthétiques obtenus par génie génétique et synthèse recombinante de produits à base de carbone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROUJEINIKOVA A.: "Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 43, 22 October 1999 (1999-10-22), pages 30811 - 30817, XP002937139 *
WARD W.: "Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan", BIOCHEMISTRY, vol. 38, no. 38, pages 12514 - 12525, XP002937138 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176299B2 (en) 1996-02-20 2007-02-13 Affinium Pharmaceuticals, Inc. Compounds
US7422749B2 (en) 1996-02-20 2008-09-09 Affinium Pharmaceuticals, Inc. Compounds
US7250285B2 (en) 1996-08-16 2007-07-31 Affinium Pharmaceuticals, Inc. Purified polypeptides from Streptococcus pneumoniae
US6753172B1 (en) 1996-08-28 2004-06-22 Affinium Pharmaceuticals, Inc. FabI
US6995254B1 (en) 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
EP1178820A4 (fr) * 1999-05-06 2003-04-23 Smithkline Beecham Corp Procedes de modulation de l'activite de fabh
EP1178820A1 (fr) * 1999-05-06 2002-02-13 SmithKline Beecham Corporation Procedes de modulation de l'activite de fabh
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
US6821746B2 (en) 2000-10-06 2004-11-23 Affinium Pharmaceuticals, Inc. Methods of screening for FabK antagonists and agonists
US7056697B2 (en) 2000-10-06 2006-06-06 Affinium Pharmaceuticals, Inc. FabK variant
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
US7033795B2 (en) 2000-10-06 2006-04-25 Affinium Pharmaceuticals, Inc. FabK variant
US7799547B2 (en) 2003-07-11 2010-09-21 Affinium Pharmaceuticals, Inc. Purified polypeptides from Staphylococcus aureus
WO2015200335A1 (fr) * 2014-06-23 2015-12-30 Joule Unlimited Technologies, Inc. Microbes photosynthétiques obtenus par génie génétique et synthèse recombinante de produits à base de carbone

Also Published As

Publication number Publication date
WO2001030988A8 (fr) 2001-09-07

Similar Documents

Publication Publication Date Title
US6951729B1 (en) High throughput screening method for biological agents affecting fatty acid biosynthesis
WO2001030988A1 (fr) Procedes de fabrication et d'utilisation de reactifs de voies de synthese d'acides gras
WO2000078935A9 (fr) Genes de voie du mevalonate
US6162618A (en) 6-phosphogluconate dehydrogenase of Streptococcus pneumoniae
US7033795B2 (en) FabK variant
US6168797B1 (en) FabF
US6294357B1 (en) FabF from Staphylococcus aureus
US6287810B1 (en) Polynucleotides encoding an undercaprenyl diphosphate synthase of staphylococcus aureus
US6110704A (en) 3-ketoacyl-ACP-reductase (FabG) of Staphylococcus aureus
US6287804B1 (en) nrdG
US7056697B2 (en) FabK variant
US6448038B1 (en) BirA from staphylococcus aureus
US6238885B1 (en) Histidine kinase
US6489139B1 (en) FabZ from Staphylococcus aureus
US6391600B1 (en) PcrA helicase
US6316237B1 (en) Respiratory nitrate reductase alpha subunit
US6352840B1 (en) pskG
US6406889B1 (en) 509hk
WO2001038345A1 (fr) Genes chimeres fabh pouvant etre regules
US6194174B1 (en) Histidine kinase, 636 HK, of staphylococcus aureus
US6352843B1 (en) YsxC from Staphylococcus aureus
EP1283675A1 (fr) Procedes de modulation de l'activite de mura
US6130069A (en) IspA from Streptococcus pneumoniae
US20050239702A1 (en) Methods of modulating FabH activity
WO2000040594A1 (fr) AcpS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WR Later publication of a revised version of an international search report
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10089019

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)